NEW YORK, Dec. 14, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Antiemetics: Technologies and Global Markets
http://www.reportlinker.com/p0341186/Antiemetics-Technologies-and-Global-Markets.html
The global market for antiemetics was nearly $2.4 billion in 2009. There was a little setback seen in 2009 in the 5-HT3 category due to weakened economy and competition within brands and generics. The market for antiemetic products is expected to reach $2.5 billion by the end of 2010 and $3.6 billion by 2015, reflecting a 7.4% compound annual growth rate (CAGR).
Although 5-HT3 antagonists have seen a decline in 2009, this category holds about half of the market. This sector is valued at an estimated $1 billion in 2010 and is expected to increase at a 3.6% compound annual growth rate (CAGR) between 2010 and 2015 to reach $1.3 billion in 2015.
NK1 receptor and dopamine antagonist and anticholinergics will experience the most growth over the forecast period. This sector is worth an estimated $582 million in 2010 and is expected to reach more than $1 billion by 2015, a 13.3% compound annual growth rate (CAGR).INTRODUCTION
STUDY OBJECTIVES
BCC's goal in conducting this study is to provide an overview of the current and future characteristics of the global market for antiemetic agents. The key objective is to present a comprehensive analysis of the current market and its future direction and the antiemetics market as an important agent as adjunct therapy for cancer patients and also other therapeutic arenas to control emesis.
This report explores present and future strategies within the antiemetic market, reason for emesis, and types of antiemetic agents used to control nausea or vomiting. The improvisation of the market, and the setbacks and the needs of the market are discussed in this report. The causes of emesis, usage of antiemetics and the types of products available to treat nausea and vomiting of each category of antiemetics are also portrayed in this report.
A detailed analysis of the antiemetic industry structure has been conducted. The revenues are broken down by region. Sales figures are estimated for the 5 year period from the end of 2010 through 2015.
Applications for antiemetics are also discussed separately in the report, with emphasis on the usage in chemotherapy-induced nausea and vomiting (CINV), post-radiotherapy nausea and vomiting, and post-operative nausea and vomiting (PONV), etc. The report also covers significant patents and their allotments in each category.
REASONS FOR DOING THIS STUDY
Emesis itself is not a disease but is stressful enough to discourage a patient, especially a patient dealing with cancer therapies. The antiemetics market has seen advancement in modern medicine. R&D spending, along with increasing competition, patent expiries, new technologies, and an international marketplace are directing this new direction. The antiemetics market has seen almost a constant growth except some setbacks in 5-HT2 category in 2009, due to the general economic downturn, but new advances and the need for good pharmacological activity of antiemetic products are influencing the market to grow. This study looks at almost all the systems affected by these factors.
Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strength and weaknesses of each system/ technology in light of the new technologies, growing competition, and changing customer needs.
INTENDED AUDIENCE
This study contributes to the areas of market growth in the antiemetic industry from the point of view of manufacturers and users. Biotechnological companies, physicians, the pharmaceutical and biopharmaceutical industries, hospitals, and research institutes will find this study to be of interest.
SCOPE OF THE STUDY
The scope of this study encompasses the biotechnology, pharmaceutical, and medical markets. BCC analyzes each market and its applications by its need for development of new medications, regulatory environment, technology involved, market projections, and market share. Technological issues include the latest trends and developments.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this market research report. BCC conducted a comprehensive search of the literature, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with various analytical/chemical/pharmaceutical/biotechnical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.
INFORMATION SOURCES
Many companies within the industry were contacted to obtain data for this study. Included were manufacturers and end users of biopharmaceutical and pharmaceutical products, through their production, research, and contract manufacturing/research lines. Data were gathered from various industry sources. BCC spoke with officials and physicians within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade, and government sources.
ABOUT THE AUTHOR
Shalini S. Dewan holds a master's degree in pharmaceutical chemistry. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are MST034C Reagents for Chromatography; IAS004B Spectroscopy, An Enduring Market; PHM006G Advanced Drug Delivery Systems: New Developments, New Technologies; PHM040A Orthopedic Drugs, Implants and Devices; HLC040C Medical Imaging Reagents and Analysis Equipment; PHM047A Pharmaceutical Regulatory Industry; and BIO014F The Dynamic Media, Sera and Reagent Market in Biotechnology.
Chapter- 1: INTRODUCTION -- Complimentary
STUDY OBJECTIVES 1
REASONS FOR DOING THIS STUDY 1
INTENDED AUDIENCE 2
SCOPE OF THE STUDY 2
METHODOLOGY 2
INFORMATION SOURCES 2
ABOUT THE AUTHOR 3
RELATED BCC RESEARCH REPORTS 3
BCC ONLINE SERVICES 3
DISCLAIMER 4
Chapter-2: EXECUTIVE SUMMARY
EXECUTIVE SUMMARY 5
SUMMARY TABLE WORLDWIDE REVENUE OF ANTIEMETICS, THROUGH 2015 ($ MILLIONS) 6
SUMMARY FIGURE WORLDWIDE REVENUE OF ANTIEMETICS, 2008-2015 ($ MILLION) 6
Chapter-3: OVERVIEW
STAGES IN NAUSEA AND VOMITING 7
TYPES OF EMESIS 8
RELATIONSHIP BETWEEN RECEPTORS AND NAUSEA 8
THE GI TRACT 9
THE CHEMORECEPTOR TRIGGER ZONE (CTZ) 9
THE VESTIBULAR APPARATUS 9
THE CEREBRAL CORTEX 10
HISTORY 10
HISTORY OF PATHOPHYSIOLOGY 10
HISTORY OF ANTIEMETIC THERAPY 10
TABLE 1 HISTORY OF ANTIEMETIC THERAPY 10
TABLE 1 (CONTINUED) 11
TABLE 2 HISTORY OF SEROTONIN AND 5-HT RECEPTORS 11
TABLE 3 HISTORY OF TACHYKININS AND NEUROKININ RECEPTORS 12
TABLE 4 HISTORY OF CORTICOSTEROIDS 12
TABLE 5 HISTORY OF DOPAMINE AND DOPAMINE RECEPTORS 12
CAUSES OF EMESIS AND ITS THERAPY 13
VESTIBULAR INVOLVEMENT 13
OBSTRUCTION 14
MIND 14
INFECTION, IRRITATION, AND INFLAMMATION 15
TOXINS 15
TABLE 6 CAUSES OF EMESIS AND THE THERAPY INVOLVED 16
Chapter-4: TYPE OF ANTIEMETIC DRUGS
TYPES OF ANTIEMETIC DRUGS 17
5-HTD— RECEPTOR ANTAGONISTS 17
TABLE 7 5-HTD— RECEPTOR ANTAGONISTS DRUG PRODUCTS AS ANTIEMETICS 18
NK1 RECEPTOR ANTAGONISTS 18
TABLE 8 5NK1 RECEPTOR ANTAGONISTS DRUG PRODUCTS AS ANTIEMETICS 19
ANTIHISTAMINES (HI ANTIHISTAMINE RECEPTOR ANTAGONISTS): 19
TABLE 9 ANTIHISTAMINES DRUG PRODUCTS AS ANTIEMETICS 19
TABLE 9 (CONTINUED) 20
DOPAMINE ANTAGONISTS 20
TABLE 10 DOPAMINE ANATAGONISTS, DRUG PRODUCTS AS ANTIEMETICS 21
STEROID-CORTICOSTEROIDS 21
TABLE 11 STEROIDS-CORTICOSTEROIDS, DRUG PRODUCTS AS ANTIEMETICS 22
CANNABINOIDS 22
TABLE 12 CANNABINOIDS, DRUG PRODUCTS AS ANTIEMETICS 23
BENZODIAZEPINES 23
TABLE 13 BENZODIAZEPINES, DRUG PRODUCTS AS ANTIEMETICS 24
ANTICHOLINERGICS 25
TABLE 14 ANTICHOLENERGIC DRUG PRODUCTS AS ANTIEMETICS 25
OTHERS 25
TABLE 15 OTHER PRODUCTS AS ANTIEMETICS 26
TABLE 16 NON-PHARMACEUTICAL THERAPIES 26
TABLE 16 (CONTINUED) 27
Chapter-5: REGULATORY ASPECTS
TABLE 17 APPROVALS OF ANTIEMETICS, 2007 TO APRIL 2010 28
TABLE 17 (CONTINUED) 29
TABLE 17 (CONTINUED) 30
TABLE 17 (CONTINUED) 31
TABLE 17 (CONTINUED) 32
TABLE 17 (CONTINUED) 33
TABLE 18 REGULATORY CHANGES OF ANTIEMETICS, 2007 TO APRIL 2010, BY ACTIVE INGREDIENT 34
TABLE 18 (CONTINUED) 35
TABLE 18 (CONTINUED) 36
TABLE 19 SAFETY ALERTS FOR ANTIEMETICS, 2007 TO APRIL 2010, BY ACTIVE INGREDIENT 36
TABLE 19 (CONTINUED) 37
REGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS 37
REGULATORY UPDATES: APPROVAL, … (CONTINUED) 38
Chapter-6: INDUSTRY STRUCTURE
MANUFACTURERS/PRODUCTS FOR ANTIEMETICS 39
TABLE 20 LEADING MANUFACTURERS OF 5-HT3 RECEPTOR ANTAGONISTS 39
TABLE 20 (CONTINUED) 40
TABLE 21 LEADING MANUFACTURERS OF NK-1 RECEPTOR ANTAGONISTS 40
TABLE 22 LEADING MANUFACTURERS OF H1 RECEPTOR ANTAGONISTS 40
TABLE 22 (CONTINUED) 41
TABLE 23 LEADING MANUFACTURERS OF DOPAMINE ANTAGONISTS 41
TABLE 23 (CONTINUED) 42
TABLE 24 LEADING MANUFACTURERS/ SUPPLIERS OF STEROIDS-CORTICOSTEROIDS 42
TABLE 25 LEADING MANUFACTURERS/ SUPPLIERS OF CANNABINOIDS 43
TABLE 26 LEADING MANUFACTURERS/ SUPPLIERS OF BENZODIAZEPINES 43
TABLE 27 LEADING MANUFACTURERS/ SUPPLIERS OF ANTICHOLINERGICS 43
MARKET SHARES OF INDUSTRY LEADERS 44
5-HT3 RECEPTOR ANATAGONISTS 44
TABLE 28 WORLDWIDE MARKET SHARES OF 5-HT3 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS, 2009 (%) 44
FIGURE 1 WORLDWIDE MARKET SHARES OF 5-HT3 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS, 2009 (%) 45
NK-1 RECEPTOR ANATAGONISTS 45
TABLE 29 WORLDWIDE MARKET SHARES OF NK-1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS, 2009 (%) 45
H1 RECEPTOR ANATAGONISTS 46
TABLE 30 WORLDWIDE MARKET SHARES OF H1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS, 2009 (%) 46
FIGURE 2 WORLDWIDE MARKET SHARES OF H1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS, 2009 (%) 47
DOPAMINE ANATAGONISTS 47
TABLE 31 WORLDWIDE MARKET SHARES OF DOPAMINE ANTAGONISTS USED AS ANTIEMETICS, 2009 (%) 47
FIGURE 3 WORLDWIDE MARKET SHARES OF DOPAMINE ANTAGONISTS USED AS ANTIEMETICS, 2009 (%) 48
STEROIDS-CORTICOSTEROIDS 48
TABLE 32 WORLDWIDE MARKET SHARES OF STEROIDS-CORTICOSTEROIDS USED AS ANTIEMETICS, 2009 (%) 48
FIGURE 4 WORLDWIDE MARKET SHARES OF STEROIDS-CORTICOSTEROIDS USED AS ANTIEMETICS, 2009 (%) 49
CANNABINOIDS 49
TABLE 33 WORLDWIDE MARKET SHARES OF CANNABINOIDS USED AS ANTIEMETICS, 2009 (%) 49
FIGURE 5 WORLDWIDE MARKET SHARES OF CANNABINOIDS USED AS ANTIEMETICS, 2009 (%) 50
BENZODIAZEPINES 50
TABLE 34 WORLDWIDE MARKET SHARES OF BENZODIAZEPINES USED AS ANTIEMETICS, 2009 (%) 50
FIGURE 6 WORLDWIDE MARKET SHARES OF BENZODIAZEPINES USED AS ANTIEMETICS, 2009 (%) 51
ANTICHOLINERGICS 51
TABLE 35 WORLDWIDE MARKET SHARES OF ANTICHOLINERGICS USED AS ANTIEMETICS, 2009 (%) 51
FIGURE 7 WORLDWIDE MARKET SHARES OF ANTICHOLINERGICS USED AS ANTIEMETICS, 2009 (%) 52
Chapter-7: NEW DEVELOPMENTS
NEW DEVELOPMENTS 53
TABLE 36 WORLDWIDE NEW DEVELOPED DRUGS SINCE 2003 54
TABLE 37 PIPELINE ANTIEMETICS 55
TABLE 37 (CONTINUED) 56
RECENT UPDATES FROM THE ANTIEMETIC WORLD 56
RECENT UPDATES FROM THE … (CONTINUED) 57
RECENT UPDATES FROM THE … (CONTINUED) 58
Chapter-8: MARKET ANALYSIS
5-HT3 RECEPTOR ANTAGONISTS 59
MARKET OVERVIEW 60
Market Overview (Continued) 61
MARKET REVENUE 62
TABLE 38 WORLDWIDE MARKET FOR 5-HT3 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, THROUGH 2015 ($ MILLIONS) 62
FIGURE 8 WORLDWIDE MARKET FOR 5-HT3 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, 2008-2015 ($ MILLIONS) 63
NK1 RECEPTOR ANTAGONISTS 63
MARKET OVERVIEW 64
MARKET REVENUE 64
TABLE 39 WORLDWIDE MARKET FOR NK-1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, THROUGH 2015 ($ MILLIONS) 65
FIGURE 9 WORLDWIDE MARKET FOR NK-1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, 2008-2015 ($ MILLIONS) 65
H1 RECEPTOR ANTAGONISTS 66
MARKET OVERVIEW 66
MARKET REVENUE 67
TABLE 40 WORLDWIDE MARKET FOR H1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, THROUGH 2015 ($ MILLIONS) 67
FIGURE 10 WORLDWIDE MARKET FOR H1 RECEPTOR ANTAGONISTS USED AS ANTIEMETICS BY REGION, 2008-2015 ($ MILLIONS) 67
DOPAMINE ANTAGONISTS 68
MARKET OVERVIEW 68
MARKET REVENUE 69
TABLE 41 WORLDWIDE MARKET FOR DOPAMINE ANTAGONISTS USED AS ANTIEMETICS BY REGION, THROUGH 2015 ($ MILLIONS) 69
FIGURE 11 WORLDWIDE MARKET FOR DOPAMINE ANTAGONISTS USED AS ANTIEMETICS BY REGION, 2008-2015 ($ MILLIONS) 70
STEROIDS -CORTICOSTEROIDS 70
MARKET OVERVIEW 70
MARKET REVENUE 71
TABLE 42 WORLDWIDE MARKET FOR STEROIDS-CORTICOSTEROIDS USED AS ANTIEMETICS BY REGION, THROUGH 2015 ($ MILLIONS) 72
FIGURE 12 WORLDWIDE MARKET FOR STEROIDS-CORTICOSTEROIDS USED AS ANTIEMETICS BY REGION, 2008-2015 ($ MILLIONS) 72
CANNABINOIDS 72
MARKET OVERVIEW 73
MARKET REVENUE 73
TABLE 43 WORLDWIDE MARKET FOR CANNABINOIDS USED AS ANTIEMETICS BY REGION, THROUGH 2015 ($ MILLIONS) 74
FIGURE 13 WORLDWIDE MARKET FOR CANNABINOIDS USED AS ANTIEMETICS BY REGION, 2008-2015 ($ MILLIONS) 74
BENZODIAZEPINES 74
MARKET OVERVIEW 75
MARKET REVENUE 75
TABLE 44 WORLDWIDE MARKET FOR BENZODIAZEPINES USED AS ANTIEMETICS BY REGION, THROUGH 2015 ($ MILLIONS) 76
FIGURE 14 WORLDWIDE MARKET FOR BENZODIAZEPINES USED AS ANTIEMETICS BY REGION, 2008-2015 ($ MILLIONS) 76
ANTICHOLINERGICS 76
MARKET OVERVIEW 77
MARKET REVENUE 77
TABLE 45 WORLDWIDE MARKET FOR ANTICHOLINERGICS USED AS ANTIEMETICS BY REGION, THROUGH 2015 ($ MILLIONS) 77
FIGURE 15 WORLDWIDE MARKET FOR ANTICHOLINERGIC USED AS ANTIEMETICS BY REGION, 2008-2015 ($ MILLIONS) 78
MARKET SHARES 78
TABLE 46 WORLDWIDE ANTIEMETICS AGENTS MARKET SHARES BY REGION, 2009 (%) 78
FIGURE 16 WORLDWIDE ANTIEMETICS AGENTS MARKET SHARES BY REGION, 2009 (%) 79
Chapter-9: MARKET BY APPLICATIONS
MARKET SHARE OF APPLICATIONS 80
TABLE 47 WORLDWIDE ANTIEMETIC MARKET SHARES, BY APPLICATION, 2009 (%) 81
FIGURE 17 WORLDWIDE ANTIEMETICS MARKET SHARES, BY APPLICATION, 2009 (%) 81
CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) 81
CHEMOTHERAPY-INDUCED NAUSEA …(CONTINUED) 82
TABLE 48 ANTIMETIC THERAPIES FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING 83
MARKET REVENUE 83
TABLE 49 GLOBAL SALES OF ANTIEMETIC DRUGS IN CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, THROUGH 2015 ($ MILLIONS) 84
FIGURE 18 GLOBAL SALES OF ANTIEMETIC DRUGS IN CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, 2008-2015 ($ MILLIONS) 84
NAUSEA AND VOMITING DUE TO MOTION SICKNESS 85
TABLE 50 ANTIEMETIC THERAPIES FOR NAUSEA AND VOMITING DUE TO MOTION SICKNESS 85
MARKET REVENUE 86
TABLE 51 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN MOTION SICKNESS, THROUGH 2015 ($ MILLIONS) 86
FIGURE 19 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN MOTION SICKNESS, 2008-2015 ($ MILLIONS) 86
POSTOPERATIVE NAUSEA AND VOMITING 87
TABLE 52 ANTIEMETIC THERAPIES FOR POSTOPERATIVE NAUSEA AND VOMITING 87
MARKET REVENUE 87
TABLE 53 GLOBAL SALES OF ANTIEMETIC DRUGS IN POSTOPERATIVE NAUSEA AND VOMITING, THROUGH 2015 ($ MILLIONS) 88
FIGURE 20 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN POSTOPERATIVE NAUSEA AND VOMITING, THROUGH 2015 ($ MILLIONS) 88
POST-RADIATION NAUSEA AND VOMITING 88
TABLE 54 ANTIEMETIC THERAPIES FOR RADIOTHERAPY INDUCED NAUSEA AND VOMITING 89
MARKET REVENUE 90
TABLE 55 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN RADIOTHERAPY-INDUCED NAUSEA AND VOMITING, THROUGH 2015 ($ MILLIONS) 90
FIGURE 21 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN RADIOTHERAPY INDUCED NAUSEA AND VOMITING, 2008-2015 ($ MILLIONS) 91
ACUTE GASTROENTERITIS 91
TABLE 56 ANTIEMETIC THERAPIES FOR ACUTE GASTROENTERITIS VOMITING 92
MARKET REVENUE 92
TABLE 57 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN ACUTE GASTROENTERITIS, THROUGH 2015 ($ MILLIONS) 92
FIGURE 22 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN ACUTE GASTROENTERITIS, 2008-2015 ($ MILLIONS) 93
OTHER CONDITIONS 93
TABLE 58 ANTIEMETIC THERAPIES FOR OTHER CONDITIONS 94
MARKET REVENUE 94
TABLE 59 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN OTHER CONDITIONS, THROUGH 2015 ($ MILLIONS) 94
FIGURE 23 GLOBAL SALES OF ANTIEMETIC DRUGS USED IN OTHER CONDITIONS, THROUGH 2015 ($ MILLIONS) 95
Chapter-10: PATENT ANALYSIS
PATENTS BY YEAR 96
TABLE 60 NUMBER OF SIGNIFICANT ANTIEMETIC PATENTS BY YEAR, 2006–2010 97
FIGURE 24 NUMBER OF ANTIEMETIC PATENTS BY YEAR, 2006–2010 97
FIGURE 25 NUMBER OF ANTIEMETIC PATENTS BY YEAR, 2006–2010 (%) 98
PATENTS BY MODE OF ADMINISTRATION 98
TABLE 61 PATENTS BY MODE/ ROUTE OF ADMINISTRATION, 2006–2010 98
FIGURE 26 PATENTS BY MODE/ ROUTE OF ADMINISTRATION, 2006–2009 99
PATENTS BY TYPE/CATEGORY 99
TABLE 62 PATENTS BY TYPE/ CATEGORY FOR ANTIEMETICS, 2006–2010 100
FIGURE 27 PATENTS BY TYPE/CATEGORY FOR ANTIEMETICS, 2006–2009 101
PATENTS BY COMPANY 101
TABLE 63 NUMBER OF U.S. PATENTS BY COMPANY FOR ANTIEMETICS, 2006–2010 102
FIGURE 28 NUMBER OF U.S. PATENTS BY COMPANY FOR ANTIEMETICS, 2006–2010 102
PATENTS BY COUNTRY 103
TABLE 64 NUMBER OF U.S. PATENTS BY COUNTRY FOR ANTIEMETICS, 2006–2010 103
FIGURE 29 NUMBER OF U.S. PATENTS BY COUNTRY FOR CONTRAST AGENTS, 2006–2010 103
TABLE 65 PATENT SHARES BY COUNTRY FOR ANTIEMETICS, 2006–2010 (%) 104
FIGURE 30 PATENT SHARES BY COUNTRY FOR ANTIEMETICS, 2006–2010 (%) 104
ANTIEMETICS PATENTS WORLDWIDE 104
TABLE 66 NUMBER OF ANTIEMETIC PATENTS ISSUED BY DIFFERENT PATENT ORGANIZATIONS WORLDWIDE, 2006–2010 105
FIGURE 31 ANTIEMETIC PATENTS ISSUED BY DIFFERENT PATENT ORGANIZATIONS WORLDWIDE, 2006–2010 106
PATENTS BY ASSIGNEE (WORLDWIDE) 106
TABLE 67 PATENTS BY ASSIGNEE (WORLDWIDE) FOR ANTIEMETICS, 2006–2010 106
FIGURE 32 PATENTS BY ASSIGNEE (WORLDWIDE) FOR ANTIEMETICS, 2006–2010 107
Chapter-11: CURRENT SITUATION OF ANTIEMETICS MARKET
MARKET RESTRAINTS 108
COMPETITION 108
COST OF THE DRUGS 109
PATENTS EXPIRATIONS 109
TABLE 68 PATENT EXPIRATIONS 109
GROWTH FACTORS 110
LIFE EXPECTANCY 110
PATENT PROTECTION 110
DRUGS PORTFOLIO MANAGEMENT 110
FUTURE OF ANTIEMETICS MARKET 110
TABLE 69 COMPARISON OF I AND II GENERATION 5-HT3 RECEPTOR ANTAGONISTS 111
Chapter-12: COMPANY PROFILES
ABBOTT LABS 112
ACTAVIS 113
AKORN, INC. AND AKORN STRIDES 113
APOTEX INC. 114
APP PHARMACEUTICALS 114
ASTELLAS PHARMA GMBH 115
AUROBINDO PHARMA 115
BAXTER HEALTHCARE CORPORATION 116
BEDFORD LABORATORIES 117
BIOVAIL PHARMACEUTICALS, INC. 117
CADILA PHARMACEUTICALS LTD. 118
CIPLA LTD. 119
CLARIS LIFESCIENCES 119
CORE PHARMA LLC 120
CYPRESS PHARMACEUTICAL, INC. 120
DR. REDDY'S LABORATORIES LTD. 121
EISAI INC. 122
GLAND PHARMA LTD 122
GLAXO SMITHKLINE 123
GLENMARK GENERICS LIMITED 124
GROUP TECHNICALE-FARMOZ S.A 124
G & W LABS 125
HAMELN PHARMACEUTICALS LTD. 125
HAWTHORN PHARMACEUTICALS, INC. 126
HELSINN HEALTHCARE SA/EISAI 126
HETERO DRUGS LIMITED 127
HIKMA FARMACEUTICA PLC 127
HOSPIRA 128
IMPAX LABS 128
INSIGHT PHARMACEUTICALS CORP. 129
IPCA LABS LTD. 130
JANSSEN (A DIVISION OF ORTHO MCNEIL JANSSEN, J & J) 130
KING PHARMACEUTICALS INC. 131
KVK-TECH, INC. 132
LUITPOLD PHARMACEUTICALS, INC. 132
MANX PHARMA LTD. 133
MEDA PHARMACEUTICALS 134
MERCK & CO., INC. 134
MYLAN 135
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LTD. 136
NOVELL PHARMACEUTICAL LABORATORIES 136
PAR PHARMACEUTICALS 137
PFIZER INC. 138
PIRAMAL HEALTHCARE LIMITED 138
PLIVA HRVATSKA DOO (TEVA GROUP COMPANY) 139
PROSTRAKAN GROUP PLC 139
ROCHE LABORATORIES (F. HOFFMANN-LA ROCHE AG) 140
ROSEMONT PHARMACEUTICALS LTD. 141
SALIX PHARMACEUTICALS INC. 142
SANOFI AVENTIS US 142
SATO PHARMACEUTICALS 143
SCHWARZ PHARMA (UCB SUBSIDIARY) 144
SOLVAY PHARMACEUTICALS (UNIMED/ABBOTT) 144
STRATIVA PHARMACEUTICALS 145
SUN PHARMACEUTICAL INDUSTRIES LTD. 145
TARO PHARMACEUTICAL INDUSTRIES LTD. 146
TEVA PHARMACEUTICAL INDUSTRIES LTD. 146
TORRENT PHARMACEUTICALS 147
WALLACE PHARMACEUTICALS LTD. 148
WATSON PHARMACEUTICALS, INC. 148
WOCKHARDT USA LLC 149
ZYDUS CADILA 149
ZYDUS PHARMS USA 150
Chapter-13: ABBREVIATIONS
TABLE 70 ABBREVIATIONS 151
TABLE 70 (CONTINUED) 152
To order this report:
Drug and Medication Industry: Antiemetics: Technologies and Global Markets
Drug and Medication Business News
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article